Menu
← Oncology Approval Tracker
FDA DECISION ·
Gavreto
pralsetinib · Blueprint Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic non-small cell lung cancer with a RET gene fusion identified by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
Added a second selective RET inhibitor option for metastatic lung cancer under accelerated approval.
What research teams should watch
Document the fusion result, prior treatment exposure and monitoring for blood-pressure changes and pneumonitis.
PRIMARY RECORDS